Hi, Shrewd!        Login  
Shrewd'm.com 
A merry & shrewd investing community
Best Of FK | Best Of | Favourites & Replies | All Boards | Post of the Week!
Search FK
Shrewd'm.com Merry shrewd investors
Best Of FK | Best Of | Favourites & Replies | All Boards | Post of the Week!
Search FK


Investment Strategies / Falling Knives
Unthreaded | Threaded | Whole Thread (4) |
Author: DTB   😊 😞
Number: of 577 
Subject: Re: FKA: NVO
Date: 01/28/2025 1:33 PM
Post New | Post Reply | Report Post | Recommend It!
No. of Recommendations: 6
Forward P/E now about 23, which isn't nosebleed by modern standards. Softened with the 1.68% dividend yield.


I didn’t expect a Monaco resident to appreciate the dividend! Plus, it’s double counting. Those dividends are just part of the P.

More importantly, Novo is the owner of the Ozempic/Wegovy/Rybelsus franchise, whose USA patent protection expires in 2026 (different in each country) whereas Lilly’s dual agonist tirzepatide is probably the better drug and has many years of patent protection left, not to mention Lilly’s triple agonist retatrutide which is even better but which is not yet licensed.

So although Novo’s P/E looks reasonable, the E is going to be challenged in the next few years and the ‘bargain price’ may just be the market applying the appropriate haircut.
Post New | Post Reply | Report Post | Recommend It!
Print the post
Unthreaded | Threaded | Whole Thread (4) |


Announcements
Falling Knives FAQ
Contact Shrewd'm
Contact the developer of these message boards.

Best Of FK | Best Of | Favourites & Replies | All Boards | Followed Shrewds